The global blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%.
Market Dynamics
Drivers
- Increasing Number of Blood Donations and Blood Donors
- Increasing Demand of Donated Blood
- Rising Prevalence of Infectious Diseases
- Growing Affordability and Adoption of NAT for Blood Screening
- Rising Awareness Regarding the Safety of Donated Blood
Do not miss out on business opportunities in Blood Screening Market
Restraints
- Capital Expenditure and Operating Costs of NAT
- Lack of Regulations Mandating the Use of NAT in Developing Countries
- Emergence of Alternative Technologies
Opportunities
- Pathogen Reduction Technology
- Multiplex tests
- Emerging economies
challenges
- Price Reduction
Browse and in-depth TOC on “ Blood Screening Market „
212 – Tables
41 – Figures
265 – Pages
This report segments the blood screening market on the basis of technology, product & service, end user, and region. Based on technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment is further sub-segmented into TMA and real-time PCR. The ELISA technology segment is further categorized into various generations and platforms. ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA. On the basis of platform, the ELISA segment is categorized into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI).
The NAT segment is expected to dominate the global blood screening market in 2016. NAT-tested blood , In addition, the rising state of the art in a disease and blood pressure segment of a patient suffering from sickle-cell anemia, thalassemia, and hemophilia serve to support the growth of this technology segment.
On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The responsents & kits segment is further sub-segmented into NAT, ELISA, and other reagents and kits. The instrument segment is categorized based on purchase and is further subsegmented into purchase and outright purchase. In 2016, the Reagents and Kits segment is expected to post the largest share of the blood screening market. The large share of this segment can be attributed to the high consumption and repeated use of reagents and kits in blood screening procedures.
On the basis of end user, the blood screening market is segmented into blood banks and hospitals. 2016. Major factors driving the growth of this segment are increasing blood pressure, increasing number of organ transplant surgeries, increasing awareness of the safety of blood, increasing number of donations worldwide, and growth in government funding to charitable trusts.
Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsample.asp?id=267747042
On the basis of region, the blood screening market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). 2016. Growth in this regional segment is driven by factors as increasing adoption of nucleic acid tests (NAT) and increasing participation of various government associations in blood donations and screening & transfusion activities.
Key players in the blood screening market include Grifols (Spain), Thermo Fisher Scientific, Inc. (US), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers (Germany) , Abbott Laboratories (US), Ortho Clinical Diagnostics, Inc. (US), Becton, Dickinson and Company (US), and Beckman Coulter, Inc. (US).
Medical Devices Market Research Reports & Consulting
About MarketsandMarkets ™
MarketsandMarkets ™ provides quantified B2B research on 30,000 high growth opportunities / threats 70% to 80% of worldwide companies‘ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets ™ for their painpoints around
Our 850 fulltime analyst and SMEs at MarketsandMarkets ™ are following the „Growth Engagement Model – GEM“. The GEM aims to identify new opportunities, identify the most important customers, write attack, avoid and defend strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets ™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets ™ is going to spend more than 10,000 companies this year for their revenue planning and help them make their innovations / disruptions early to the market.
MarketsandMarkets‘ flagship competitive intelligence and market research platform, ‚Knowledge Store‘, joins over 200,000 markets and entire value chains for the understanding of the marketplace.
Contact:
Mr. Shelly Singh
MarketsandMarkets ™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com